Mixed News from Incyte Free

Incyte discontinued development of five oncology drugs—two oral PD-L1 inhibitors, a LAG-3 mAb, a TIM-3 mAb, and a LAG-3xPD1 bispecific antibody—to “focus on innovative high-impact clinical programs.” However, during an earnings call with investors, executives also announced positive topline results from two phase III clinical trials evaluating retifanlimab (Zynyz). In squamous cell anal carcinoma, the humanized mAb targeting PD1 met its primary endpoint of progression-free survival; in non–small cell lung cancer, the drug met its primary endpoint of overall survival. Full results will be shared later this year.